SV2002000435A - Formulaciones estabilizadas de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metroxifenil)benzo[b]tiofeno y sus sales. ref. x-13203 - Google Patents
Formulaciones estabilizadas de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metroxifenil)benzo[b]tiofeno y sus sales. ref. x-13203Info
- Publication number
- SV2002000435A SV2002000435A SV2001000435A SV2001000435A SV2002000435A SV 2002000435 A SV2002000435 A SV 2002000435A SV 2001000435 A SV2001000435 A SV 2001000435A SV 2001000435 A SV2001000435 A SV 2001000435A SV 2002000435 A SV2002000435 A SV 2002000435A
- Authority
- SV
- El Salvador
- Prior art keywords
- benzo
- salts
- metroxyphenyl
- phenoxi
- etoxi
- Prior art date
Links
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A FORMULACIONES FARMACEUTICAS QUE CONTIENEN 6-HIDROXI-3-(4-METOXIFENIL)BENZO[B]TIOFENO O UNA SAL DEL MISMO; ESTABILIZADAS ANTE LA OXIDACION U OTRAS FORMAS DE DESCOMPOSICION POR LA INCORPORACION DE UN AGENTE ESTABILIZANTE SELECCIONADO ENTRE METIONINA, ACETILCISTENIA, CISTENIA O SALES DE LAS MISMAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20323500P | 2000-05-08 | 2000-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2002000435A true SV2002000435A (es) | 2002-10-24 |
Family
ID=22753086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2001000435A SV2002000435A (es) | 2000-05-08 | 2001-05-07 | Formulaciones estabilizadas de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metroxifenil)benzo[b]tiofeno y sus sales. ref. x-13203 |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1357903B1 (es) |
| JP (1) | JP2003535827A (es) |
| KR (1) | KR100806992B1 (es) |
| CN (1) | CN1283250C (es) |
| AR (1) | AR028401A1 (es) |
| AT (1) | ATE348605T1 (es) |
| AU (2) | AU2001255310C1 (es) |
| BR (1) | BR0110620A (es) |
| CA (2) | CA2691739A1 (es) |
| CZ (1) | CZ20023651A3 (es) |
| DE (1) | DE60125416T2 (es) |
| DZ (1) | DZ3376A1 (es) |
| EA (1) | EA004871B1 (es) |
| EC (1) | ECSP014066A (es) |
| EG (1) | EG24223A (es) |
| ES (1) | ES2276784T3 (es) |
| HR (1) | HRP20020883A2 (es) |
| HU (1) | HUP0302190A3 (es) |
| IL (2) | IL152699A0 (es) |
| MX (1) | MXPA02010923A (es) |
| NO (1) | NO20025219D0 (es) |
| NZ (1) | NZ521393A (es) |
| PE (1) | PE20011255A1 (es) |
| PL (1) | PL365472A1 (es) |
| SK (1) | SK286346B6 (es) |
| SV (1) | SV2002000435A (es) |
| TW (1) | TWI225787B (es) |
| UA (1) | UA77941C2 (es) |
| WO (1) | WO2001085147A2 (es) |
| ZA (1) | ZA200207651B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
| WO2005027932A1 (ja) * | 2003-09-22 | 2005-03-31 | Nisshin Kyorin Pharmaceutical Co., Ltd. | 変色改善された5−アミノサリチル酸固形製剤およびその保存方法 |
| WO2016024369A1 (ja) * | 2014-08-13 | 2016-02-18 | テバ製薬株式会社 | がん治療用医薬組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA44710C2 (uk) * | 1995-02-28 | 2002-03-15 | Елі Ліллі Енд Компані | Похідні бензотіофену, спосіб їх одержання (варіанти), проміжні сполуки, фармацевтична композиція |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| ZA200003837B (en) * | 1999-07-29 | 2002-01-28 | Lilly Co Eli | A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. |
| AU6335600A (en) * | 1999-07-29 | 2001-02-19 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
| EP1204655B1 (en) * | 1999-07-29 | 2003-10-01 | Eli Lilly And Company | A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
-
2001
- 2001-04-30 SK SK1565-2002A patent/SK286346B6/sk not_active IP Right Cessation
- 2001-04-30 JP JP2001581801A patent/JP2003535827A/ja active Pending
- 2001-04-30 NZ NZ521393A patent/NZ521393A/en unknown
- 2001-04-30 DE DE60125416T patent/DE60125416T2/de not_active Expired - Fee Related
- 2001-04-30 HU HU0302190A patent/HUP0302190A3/hu unknown
- 2001-04-30 CA CA002691739A patent/CA2691739A1/en not_active Abandoned
- 2001-04-30 EA EA200201186A patent/EA004871B1/ru not_active IP Right Cessation
- 2001-04-30 MX MXPA02010923A patent/MXPA02010923A/es active IP Right Grant
- 2001-04-30 IL IL15269901A patent/IL152699A0/xx unknown
- 2001-04-30 AU AU2001255310A patent/AU2001255310C1/en not_active Ceased
- 2001-04-30 EP EP01928454A patent/EP1357903B1/en not_active Expired - Lifetime
- 2001-04-30 CN CNB018091296A patent/CN1283250C/zh not_active Expired - Fee Related
- 2001-04-30 CZ CZ20023651A patent/CZ20023651A3/cs unknown
- 2001-04-30 UA UA2002118788A patent/UA77941C2/uk unknown
- 2001-04-30 ES ES01928454T patent/ES2276784T3/es not_active Expired - Lifetime
- 2001-04-30 HR HR20020883A patent/HRP20020883A2/hr not_active Application Discontinuation
- 2001-04-30 AT AT01928454T patent/ATE348605T1/de not_active IP Right Cessation
- 2001-04-30 PL PL01365472A patent/PL365472A1/xx not_active Application Discontinuation
- 2001-04-30 DZ DZ013376A patent/DZ3376A1/xx active
- 2001-04-30 BR BR0110620-1A patent/BR0110620A/pt not_active Application Discontinuation
- 2001-04-30 WO PCT/US2001/011736 patent/WO2001085147A2/en not_active Ceased
- 2001-04-30 CA CA002408563A patent/CA2408563A1/en not_active Abandoned
- 2001-04-30 AU AU5531001A patent/AU5531001A/xx active Pending
- 2001-04-30 KR KR1020027014923A patent/KR100806992B1/ko not_active Expired - Fee Related
- 2001-05-02 TW TW090110500A patent/TWI225787B/zh not_active IP Right Cessation
- 2001-05-02 AR ARP010102074A patent/AR028401A1/es unknown
- 2001-05-04 PE PE2001000402A patent/PE20011255A1/es not_active Application Discontinuation
- 2001-05-05 EG EG20010461A patent/EG24223A/xx active
- 2001-05-07 SV SV2001000435A patent/SV2002000435A/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004066A patent/ECSP014066A/es unknown
-
2002
- 2002-09-23 ZA ZA200207651A patent/ZA200207651B/en unknown
- 2002-10-31 NO NO20025219A patent/NO20025219D0/no not_active Application Discontinuation
- 2002-11-07 IL IL152699A patent/IL152699A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024874A1 (es) | Composiciones bactericidas | |
| MXPA02011303A (es) | Nueva composicion farmaceutica. | |
| UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
| GT199900072AA (es) | Jarabe antihistaminico estabilizado | |
| DK1605932T3 (da) | Intranasal formulering af rotigotin | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| ES2183583T3 (es) | Agente con efecto antidepresivo, que contiene pramipexol y sertralina. | |
| UY26716A1 (es) | Emulsiones estables para productos cosméticos. | |
| PA8518801A1 (es) | Derivados de 2-aminocarbonil-9h-purina | |
| BR0012752A (pt) | Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina | |
| GT199800101A (es) | Composicion farmaceutica solida que contiene un derivado de benzofurano. | |
| AR012504A1 (es) | Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion. | |
| AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
| DE50010978D1 (de) | Kosmetische Stiftzubereitung | |
| SV1998000119A (es) | Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv | |
| BR0113062A (pt) | Derivados de heterociclilalquilazol e seu emprego como agente para o combate de parasitas | |
| ES479423A1 (es) | Procedimiento para la preparacion de 2-2-tenoiltio-propio- nil-glicina. | |
| ES2164310T3 (es) | Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina. | |
| AR047279A1 (es) | Composicion detergente liquida | |
| SV2002000435A (es) | Formulaciones estabilizadas de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metroxifenil)benzo[b]tiofeno y sus sales. ref. x-13203 | |
| ES2033379T3 (es) | Soluciones acuosas de clorhidrato de doxorubicina. | |
| GT200100218A (es) | Compuesto agroquimico. | |
| ITMI20032614A1 (it) | Nuova composizione comprendente cs | |
| HN2000000090A (es) | Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica. | |
| DE60136064D1 (de) | Wässrige flüssige preparation von pranoprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |